Mauro Di Ianni
Overview
Explore the profile of Mauro Di Ianni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brocco D, Simeone P, Marino P, De Bellis D, DAscanio F, Colasante G, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941866
Background: Colorectal cancer is among the most prevalent causes of tumor-related deaths worldwide. Antiangiogenic therapy represents a cornerstone of metastatic CRC treatment, and biomarkers are advocated for the optimization of...
2.
Lanuti PhD P, Guardalupi F, Corradi PhD G, Florio PhD R, Brocco MD PhD D, Veschi PhD S, et al.
Blood Adv
. 2025 Feb;
PMID: 39903124
Chimeric Antigen Receptor (CAR) T cell-derived Extracellular Vesicles (EVs) might represent a new therapeutic tool for boosting CAR-T cell antileukemic effects. Here, a cohort of 22 patients infused with CD19.CAR-T...
3.
Ranalli P, Baldoni S, Bruno D, Di Ianni M
Mediterr J Hematol Infect Dis
. 2024 Sep;
16(1):e2024067.
PMID: 39258184
No abstract available.
4.
Ranalli P, Natale A, Guardalupi F, Santarone S, Canto C, La Barba G, et al.
Front Oncol
. 2024 Jul;
14:1396435.
PMID: 38966064
New available drugs allow better control of systemic symptoms associated with myelofibrosis (MF) and splenomegaly but they do not modify the natural history of progressive and poor prognosis disease. Thus,...
5.
Liberatore C, Fioritoni F, Di Ianni M
Front Oncol
. 2024 Jun;
14:1402106.
PMID: 38894872
The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Thus,...
6.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, et al.
Am J Hematol
. 2024 Jun;
99(8):1462-1474.
PMID: 38877813
Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia...
7.
Piro A, Cufaro M, Lanuti P, Brocco D, De Lellis L, Florio R, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791876
Pancreatic cancer (PC) has a poor prognosis and displays resistance to immunotherapy. A better understanding of tumor-derived extracellular vesicle (EV) effects on immune responses might contribute to improved immunotherapy. EVs...
8.
Santoro N, Salutari P, Di Ianni M, Marra A
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673842
The treatment of acute myeloid leukemia (AML) with adverse genetics remains unsatisfactory, with very low response rates to standard chemotherapy and shorter durations of remission commonly observed in these patients....
9.
Di Ianni M, Liberatore C, Santoro N, Ranalli P, Guardalupi F, Corradi G, et al.
Cells
. 2024 Jan;
13(2).
PMID: 38247827
GvHD still remains, despite the continuous improvement of transplantation platforms, a fearful complication of transplantation from allogeneic donors. Being able to separate GvHD from GvL represents the greatest challenge in...
10.
Mazzucconi M, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, et al.
Blood Adv
. 2024 Jan;
8(6):1529-1540.
PMID: 38231017
A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia...